Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:2.7.7.6 (RNA polymerase)
 34,946 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The author gives a survey of groups of substances which have a marked and selective effect on HI thus serving as potential chemotherapeutical means against AIDS. They can be divided into three groups: 1. anionic substances, 2. 2, 3-dideoxynucleoside analogues and 3. sulphate polysaccharides. The mechanism of the effect of the substances of the 2nd group probably inhibits reverse HIV transcriptase. The substances of the 3rd group are to prevent adsorption of virus particles by the cells. The substances of the 1st group inhibit HIV transcriptase but also interfere with the adsorption process of the virus particles, or with other stages and phases of the HIV replication cycle. The crystallized substances of these groups should be further studied as potential therapeutic agents for the treatment of AIDS and other retrovirus infections (PMEA, D4T, dextran-sulphate, pentosan, polysulphate and others). The survey also includes information on the so-called anti-sense RNA.
 ...
PMID:[Perspectives in AIDS chemotherapy]. 257 16

The reverse-transcriptase inhibitor lamivudine (Zeffix, GlaxoSmithKline) is often used to treat chronic infection with hepatitis B virus (HBV) until resistance develops. Treatment may then be switched to the reverse-transcriptase inhibitor adefovir (Hepsera, Gilead), which has a lower frequency of resistance. Here, we describe three cases of primary adefovir resistance that were sensitive to tenofovir (Viread, Gilead). All three cases involved a rare HBV variant with a valine at position 233 of the reverse-transcriptase domain instead of isoleucine (rtI233V), as in the wild-type virus. This HBV variant also displayed resistance to adefovir and sensitivity to tenofovir in vitro.
 ...
PMID:Variant of hepatitis B virus with primary resistance to adefovir. 1685 78